Coronary/Structural Heart

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leading artificial intelligence (AI)-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has included its low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval allows outpatient settings to receive […]

PercAssist’s PSCA System – Intrapericardial Mechanical Circulatory Support (MCS) System for Cardiogenic Shock Presented at the TCT24

SANTA CLARA, Calif.–(BUSINESS WIRE)–PercAssist, Inc., a medical device company developing innovative technology for extravascular / extracardiac Mechanical Circulatory Support to provide hemodynamic improvements for patients in cardiogenic shock (CS), today announced that new data was presented at two sessions at the Transcatheter Cardiovascular Therapeutics (TCT24) Conference in Washington, DC, Oct. […]

Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule

Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers November 04, 2024 07:05 AM Eastern Standard Time BOSTON–(BUSINESS WIRE)–Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare & Medicaid Services (CMS) that will significantly increase the reimbursement for cardiac computed […]

CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025

MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) assigned the Barostim procedure to New Technology Ambulatory Payment Classification (APC) 1580. The APC payment of approximately $45,000 will continue in 2025, […]

Acarix Expands U.S. Reimbursement Coverage for CADScor System for use in Emergency and Outpatient Settings

MALMÖ, Sweden, Nov. 4, 2024 /PRNewswire/ — Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has decided that the CPT code 0716T – the CADScor® System – shall be assigned to APC 5733…

Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024

Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET SAN DIEGO, Oct. 31,…

Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months

WASHINGTON–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study evaluating the safety and performance of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) for the treatment of moderate to severely calcified coronary artery lesions demonstrating safety […]

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading cardiovascular digital health company, today announced the results of its seminal research on the real-world impact of clinical presentation among patients with moderate or greater aortic stenosis (AS) undergoing aortic valve replacement (AVR). Presented by Philippe Généreux, MD, Director of the Structural Heart […]

Cardiawave Announces Positive Six-Month Data from Valvosoft Pivotal Study at Transcatheter Cardiovascular Therapeutics (TCT) Conference

WASHINGTON–(BUSINESS WIRE)–Cardiawave SA, developer of the groundbreaking Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis (CAS), today announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5% of patients, substantially improving hemodynamics […]